{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Yes"},{"measurements":[{"groupId":"OG000","value":"15"}],"title":"No"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"The primary efficacy endpoint for the study is the ORR. The ORR is defined as the number of patients with CR and PR divided by the number of patients in the analysis set. Tumor response will be defined as best response based on local investigator's assessment according to RECIST criteria v.1.1.","groups":[{"description":"Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.\n\nRetifanlimab: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.","id":"OG000","title":"Interventional Arm"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From baseline until disease progression or treatment discontinuation, up to 10.3 months","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}